D. Boral Capital Initiates Coverage on Checkpoint Therapeutics (NASDAQ:CKPT)

D. Boral Capital assumed coverage on shares of Checkpoint Therapeutics (NASDAQ:CKPT - Free Report) in a report released on Monday, MarketBeat.com reports. The firm issued a buy rating and a $9.00 price target on the stock.

CKPT has been the subject of several other research reports. HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Checkpoint Therapeutics in a research note on Monday, December 16th. Lake Street Capital raised their price objective on Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a "buy" rating in a research report on Monday, December 16th.

Checkpoint Therapeutics Trading Up 1.3 %

CKPT stock traded up $0.04 during mid-day trading on Monday, hitting $3.20. 664,158 shares of the company were exchanged, compared to its average volume of 901,020. The company has a market capitalization of $156.27 million, a PE ratio of -1.74 and a beta of 1.36. The firm has a fifty day simple moving average of $3.64 and a 200 day simple moving average of $2.87. Checkpoint Therapeutics has a twelve month low of $1.38 and a twelve month high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.08). As a group, sell-side analysts anticipate that Checkpoint Therapeutics will post -0.91 earnings per share for the current year.

Insider Activity at Checkpoint Therapeutics

In other news, CEO James F. Oliviero III sold 220,230 shares of Checkpoint Therapeutics stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $3.38, for a total value of $744,377.40. Following the completion of the transaction, the chief executive officer now owns 3,194,583 shares of the company's stock, valued at $10,797,690.54. This trade represents a 6.45 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO William Garrett Gray sold 268,432 shares of Checkpoint Therapeutics stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $4.01, for a total transaction of $1,076,412.32. Following the transaction, the chief financial officer now directly owns 1,032,754 shares of the company's stock, valued at approximately $4,141,343.54. This trade represents a 20.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Checkpoint Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC raised its holdings in Checkpoint Therapeutics by 41.2% in the 3rd quarter. Geode Capital Management LLC now owns 427,651 shares of the company's stock valued at $958,000 after buying an additional 124,787 shares during the last quarter. B. Riley Wealth Advisors Inc. boosted its stake in Checkpoint Therapeutics by 366.3% during the second quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company's stock worth $493,000 after acquiring an additional 180,050 shares in the last quarter. PVG Asset Management Corp grew its stake in shares of Checkpoint Therapeutics by 9.2% in the 3rd quarter. PVG Asset Management Corp now owns 149,870 shares of the company's stock valued at $336,000 after buying an additional 12,676 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Checkpoint Therapeutics by 160.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company's stock valued at $291,000 after acquiring an additional 80,000 shares in the last quarter. Finally, State Street Corp increased its holdings in Checkpoint Therapeutics by 32.2% during the 3rd quarter. State Street Corp now owns 94,424 shares of the company's stock worth $212,000 after purchasing an additional 23,000 shares in the last quarter. Institutional investors and hedge funds own 22.00% of the company's stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.